XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Additions and Returns of Product Rights (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combinations [Abstract]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2021
$6,515,627 
Cash payment of royalty during the period(777,855)
Change in fair value of contingent consideration included in operating expenses(1,550,241)
Contingent consideration earned and accrued in operating expenses631,608 
Balance at September 30, 2022
$4,819,139 
The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.
Balance at January 3, 2022$3,946,716 
Cash payment of royalty during the period(339,721)
Change in fair value of contingent consideration included in operating expenses498,333 
Contingent consideration earned and accrued in operating expenses430,317 
Balance at September 30, 2022
$4,535,645 
Schedule of Dissolution Payments
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not incur expenses associated with these payments from Clinigen.
Three months ended September 30,Nine months ended September 30,
2022202120222021
Revenues$— $496,787 $— $1,491,004 
Income from discontinued operations$— $496,787 $— $1,491,004